Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 209 of the 211 references it cites were found in a registry or an index.
Abstract
The glucagon-like peptide-1 (GLP-1) is a pleiotropic hormone well known for its incretin effect in the glucose-dependent stimulation of insulin secretion. However, GLP-1 is also produced in the brain and displays a critical role in neuroprotection and inflammation by activating the GLP-1 receptor signaling pathways. Several studies in vivo and in vitro using preclinical models of neurodegenerative diseases show that GLP-1R activation has anti-inflammatory properties. This review explores the molecular mechanistic action of GLP-1 RAS in relation to inflammation in the brain. These findings update our knowledge of the potential benefits of GLP-1RAS actions in reducing the inflammatory response. These molecules emerge as a potential therapeutic tool in treating neurodegenerative diseases and neuroinflammatory pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic processing of proglucagon. NTS: nucleus of the solitary tract; GRPP: glicentin-related polypeptide; IP-1: intervening peptide-1; IP-2: intervening peptide-2; GLP-1: glucagon-like peptide-1; GLP-2: glucagon-like peptide-2; MPGF: major proglucagon fragment; PCSK1: prohormone convertase 1/3; PCSK2: prohormone convertase 2. Modified from [36]. Created with Biorender.com.](https://figures.cochat.ai/paper-figures/b03e4d8dfc0940aca0935cc5c49966ed/anti-inflammatory-effects-of-glp-1-receptor-activation-in-the-brain-in-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs can alleviate neuroinflammation by acting on the nervous system, thereby offering additional relief from pain in patients.6,409,410”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs play a neuroprotective role in neurons by facilitating neuronal survival and promoting neuronal growth, thereby preserving the structural and functional integrity of synapses.6,14”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs are anti-inflammatory because they control the signals that immune cells send and receive.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“Although it is well established that GLP-1RA’s anti-inflammatory effects originate from their impact on immune cell signaling, additional in-depth investigation into the underlying molecular pathways is required.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs may modulate inflammatory responses since GLP-1 receptors are present in immune cells such as macrophages, monocytes, and lymphocytes.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [24]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Neural regulation of endocrine and autonomic stress responses
Ulrich-Lai, Y. M., & Herman, J. P. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2647 · Cited by 3,318 · cited 2×
“Other areas of the brainstem that control the autonomic function including the limbic forebrain regions [36,48,50], areas of the mesolimbic reward system related to control of feeding and motivation to feed [36,51,52], or structures implicated in the regulation of the stress response and the HPA axis, learning and mem…”
BackgroundKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“24,35 Through their interactions with GLP-1RAs, immune cell signals are modulated inside the cell.”
BackgroundInfluentialGlucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
“Frontiers in Immunology 08 mouse model of Alzheimer’s disease reduced the inflammatory response in the cortex by decreasing the number of activated microglia (60, 65, 107, 124, 125).”
BackgroundMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“Because the health benefits of obesity treatment generally outweigh these temporary challenges,”
McGarry, A., Rosanbalm, S., Leinonen, M., Olanow, C. W., To, D., Bell, A., Lee, D., Chang, J., Dubow, J., Dhall, R., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00378-2 · Cited by 153
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
“In experimental studies, obesity-related hypothalamic inflammation can cause uncoupling of energy intake compared with expenditure [145]; preclinical studies suggest that GLP-1 receptor activation may modulate inflammatory and immune responses that affect the brain [146].”
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Siddeeque, N., Hussein, M. H., Abdelmaksoud, A., Bishop, J., Attia, A. S., Elshazli, R. M., Fawzy, M. S., & Toraih, E. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113537 · Cited by 103
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias
Tang, H., Donahoo, W. T., DeKosky, S. T., Lee, Y. A., Kotecha, P., Svensson, M., Bian, J., & Guo, J. S. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0353 · Cited by 118
Fan, Y., Liu, Y., Shao, C., Jiang, C., Wu, L., Xiao, J., & Tang, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125486 · Cited by 62
Kong, F., Wu, T., Dai, J., Zhai, Z., Cai, J., Zhu, Z., Xu, Y., & Sun, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205207 · Cited by 54
Lv, C., Han, S., Sha, Z., Liu, M., Dong, S., Zhang, C., Li, Z., Zhang, K., Lu, S., Xu, Z., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14308 · Cited by 52
“18 Studies have demonstrated that the number of amyloid beta and dense-core plaques in the cortex of Alzheimer's mice model APP/PS1 mice treated with liraglutide (GLP-1R agonist) decreased by 40%– 50%, while the level of soluble amyloid oligomers decreased by 25%.”
BackgroundInfluentialGlucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain
Diz-Chaves, Y., Mastoor, Z., Spuch, C., Lamas, J. A., González-Matías, L. C., & Mallo, F. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.389626 · Cited by 46
Self-citationZhang, Y., Tang, C., He, Y., Zhang, Y., Li, Q., Zhang, T., Zhao, B., Tong, A., Zhong, Q., & Zhong, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117540 · Cited by 36
Lv, R., Zhao, Y., Wang, X., He, Y., Dong, N., Min, X., Liu, X., Yu, Q., Yuan, K., Yue, H., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113222 · Cited by 54
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Beyond Dopamine: Novel Therapeutic Pathways for Parkinson's Disease Through Receptor Signaling
Bhushan, R., Goel, F., & Singh, S. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273325667241212041540 · Cited by 37
Wang, Z.-J., Han, W.-N., Chai, S.-F., Li, Y., Fu, C.-J., Wang, C.-F., Cai, H.-Y., Li, X., Wang, X., Hölscher, C., et al. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.022 · Cited by 35
McIntyre, R. S., Rasgon, N., Goldberg, J. F., Wong, S., Le, G. H., Mansur, R. B., Rosenblat, J. D., Teopiz, K. M., & Stahl, S. M. (2025) · CNS Spectrums · doi:10.1017/s1092852925000124 · Cited by 40
Sagy, Y. W., Ramot, N., Battat, E., Arbel, R., Reges, O., Dicker, D., & Lavie, G. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103213 · Cited by 34
The promise of GLP-1 receptor agonists for neurodegenerative diseases
Athauda, D. S., Greig, N. H., Meissner, W. G., Foltynie, T., & Gandhi, S. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194745 · Cited by 43
“GLP-1RAs also upregulate sirtuin-1 (SIRT1) indirectly (53), which deacetyl-ates autophagy-related proteins and promotes autophagosome formation.”
Kuthati, Y., Davuluri, V. N. G., & Wong, C. (2025) · Biomolecules · doi:10.3390/biom15050622 · Cited by 32
“GLP-1RAs may modulate pain transmission in the CNS by interacting with pain pathways in the brain and spinal cord [101].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Emerging insights into the impact of systemic metabolic changes on tumor-immune interactions
Cote, A. L., Munger, C. J., & Ringel, A. E. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115234 · Cited by 29
Yu, S., Wang, Y., Shen, H., Bae, E.-K., Li, Y., Sambamurti, K., Tones, M. A., Zaleska, M. M., Hoffer, B. J., & Greig, N. H. (2024) · GeroScience · doi:10.1007/s11357-024-01116-0 · Cited by 28
“The activation of the GLP-1R on neurons induces potent neurotrophic and neuroprotective actions in cellular and animal models of neural injury and neurodegeneration [13, 17–19], including PD [18, 20–25].”
BackgroundMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Deng, S., Chen, Z., & Shi, Y. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01486-8 · Cited by 30
“GLP-1R is expressed on neurons and glial cells across various brain regions [106].”
Hallaj, S., Halfpenny, W., Chuter, B., Weinreb, R. N., Baxter, S. L., & Cui, Q. N. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.08.030 · Cited by 29
Hölscher, C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01226-z · Cited by 30
“GLP-1 plays a role as an anti-inflammatory cytokine, and glia cells need to express the receptor to receive the signal [116–118].”
Does gut brain axis has an impact on Parkinson’s disease (PD)?
Elangovan, A., Dahiya, B., Kirola, L., Iyer, M., Jeeth, P., Maharaj, S., Kumari, N., Lakhanpal, V., Michel, T. M., Rao, K. R. S. S., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102171 · Cited by 23
Aranäs, C., Caffrey, A., Edvardsson, C. E., Schmidt, H. D., & Jerlhag, E. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.07.001 · Cited by 31
Noguchi, T., Katoh, H., Nomura, S., Okada, K., & Watanabe, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1342944 · Cited by 20
Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Giordano, V., Giacobbe, I., Scherillo, M., Gabrielli, D., Maurea, C., Barbato, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011299 · Cited by 23
Breit, S., & Hubl, D. (2025) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2025.107415 · Cited by 29
Yang, Y., Liu, W., Zhang, Z., zhang, Y., Wang, X., Wang, J., Cai, H., Liu, Y., Meng, R., Fu, Y., et al. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103414 · Cited by 19
GLP-1/Sigma/RAGE receptors: An evolving picture of Alzheimer's disease pathology and treatment
Neha, N., Wali, Z., Pinky, P., Hattiwale, S. H., Jamal, A., & Parvez, S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102134 · Cited by 20
Lymperopoulos, A., Borges, J. I., & Stoicovy, R. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060693 · Cited by 23
“GLP-1 is synthesized as a fragment of the much larger pre-hormone polypeptide proglucagon, which contains glucagon, GLP-2, and other incretin hormone fragments [3].”
BackgroundExploring the link between GLP-1 receptor agonists and dementia: A comprehensive review
Chuansangeam, M., Phadungsaksawasdi, P., Park, H. J., & Yang, Y. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251342182 · Cited by 31
Stoicovy, R. A., Cora, N., Perez, A., Nagliya, D., Calvo, G. D., Lopez, T. B., Weinstein, E., Borges, J. I., Maning, J., & Lymperopoulos, A. (2024) · Inflammation Research · doi:10.1007/s00011-024-01950-0 · Cited by 19
Yang, M., Jia, M., Cai, M., Feng, X., Huang, L., & Yang, J. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06840-9 · Cited by 18
Ma, J., Liu, Y., Hu, J., Liu, X., Yin, X., Xia, W., Shen, Z., Kong, X., Wu, X., Mao, L., et al. (2024) · Endocrine · doi:10.1007/s12020-024-04013-w · Cited by 20
“Notably, stimulation of GLP-1R has been found to increase cerebral blood fl ow by expanding the vasculature, which further mediates adaptive neuroprotective effects in ischemic stroke [24].”
Glucagon-like peptide-1 receptor agonism and end-organ protection
Daniels, S. J., Karlsson, C., Schrauwen, P., & Parker, V. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.01.002 · Cited by 20
Llach, C.-D., Badulescu, S., Tabassum, A., Shah, H., Gill, H., Le, G. H., Vieta, E., McIntyre, R. S., Rosenblat, J. D., & Mansur, R. B. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03261-0 · Cited by 21
“GLP-1 is produced by preproglucagon neurons in the NST and projects to the hypothalamus and brainstem, in fl uencing autonomic function and stress adaptation [88].”
Elmaaboud, M. A. A., Kabel, A. M., Borg, H. M., Magdy, A. A., Kabel, S. M., Arafa, E. A., Alsufyani, S. E., & Arab, H. H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117026 · Cited by 16
Seizure recurrence after GLP ‐1 receptor agonist initiation in adults with epilepsy
AbuAlrob, M. A., Hussein, A., Abdellatif, R., Itbaisha, A., Zammar, K., & Mesraoua, B. (2026) · Epilepsia · doi:10.1111/epi.70022 · Cited by 14
“8 11 These mechanisms support the observed association between GLP-1 RA use and reduced recurrence in our cohort.”
GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
Panfili, E., Frontino, G., & Pallotta, M. T. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1171091 · Cited by 16
Inan, S., Wilson, R. P., & Tükel, Ç. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107693 · Cited by 16
McLaughlin, S. A., Davila, N., Shields, C., Bineshfar, N., Banaee, T., & Williams, B. K. (2025) · Retina · doi:10.1097/iae.0000000000004616 · Cited by 16
Bhardwaj, M., Upmanyu, K., & Upadhyay, S. (2026) · Genes and Immunity · doi:10.1038/s41435-026-00388-0 · Cited by 17
The protective role of GLP-1 in neuro-ophthalmology
Sheth, S., Patel, A., Foreman, M. A., Mumtaz, M., Reddy, A., Sharaf, R., Sheth, S., & Lucke-Wold, B. P. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00015 · Cited by 15
“They are endogenously sourced from PPG neurons that are situated caudally in the solitary tract of the brainstem [47, 48].”
BackgroundBaral, B., Chauhan, C., Mishra, T., & Kaundal, R. K. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01584-z · Cited by 13
“Activation of these receptors has been linked to anti-inflammatory (Diz-Chaves et al. 2022 ) and neurogenic effects, both of which are relevant for mitigating TBI-induced neurodegeneration.”
Zhang, Y., Wang, C., Wang, Y., & Wang, T. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13301-y · Cited by 12
“Through their central nervous system actions and neuroprotective mechanisms, GLP-1RAs may improve PD symptoms and delay the progression in patients [13].”
Turcano, P., Savica, R., & Benarroch, E. E. (2024) · Neurology · doi:10.1212/wnl.0000000000209781 · Cited by 16
Semi-supervised meta-learning elucidates understudied molecular interactions
Wu, Y., Xie, L., Liu, Y., & Xie, L. (2024) · Communications Biology · doi:10.1038/s42003-024-06797-z · Cited by 11
“GLP1R activation is known to reduce in fl ammation, suggesting that TMAO inhibition of GLP1R might increase in fl ammation 44,45 .”
Alhomoud, I. S., Wheeler, S. E., & Dixon, D. L. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0038 · Cited by 14
AbuAlrob, M. A., Itbaisha, A., Abujwaid, Y. K., Abulehia, A., Hussein, A., & Mesraoua, B. (2025) · Journal of Alzheimer's Disease Reports · doi:10.1177/25424823251388650 · Cited by 10
Green, C., Zaman, V., Blumenstock, K., Banik, N. L., & Haque, A. (2025) · Biomedicines · doi:10.3390/biomedicines13010132 · Cited by 13
“…a Biomedicines 2025 , 13 , x FOR PEER higher risk of developing PD. Studies performed on the metabolic peptide, PP, regarding neuroinflammation have allowed researchers to find a connection between the release of PP and the brain, as its receptors have been discovered in the vagus nerve [72,75–77].”
Tang, H., Donahoo, W. T., DeKosky, S. T., Lee, Y. A., Svensson, M., Bian, J., & Guo, J. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70161 · Cited by 11
“18,33,34 (c) modulation of amyloid metabolism: Some studies have suggested that GLP-1RAs may influence amyloid processing and clearance in the brain.”
The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
Harej, A., Pilipović, K., Belančić, A., Juretić, L., Vitezić, D., & Mršić‐Pelčić, J. (2024) · Pharmaceuticals · doi:10.3390/ph17101313 · Cited by 11
Alhowail, A. H., Aldawsari, M. F., & Aldubayan, M. A. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s525690 · Cited by 10
“31,32 To date, no clinical studies have elucidated the”
Khine, H. E. E., Mangmool, S., & Parichatikanond, W. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178233 · Cited by 9
Giofrè, F., Zaffina, I., Pelle, M. C., & Arturi, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1696419 · Cited by 12
Potential applications of engineered bacteria in disease diagnosis and treatment
Luo, Z., Qi, Z., Luo, J., & Chen, T. (2024) · Microbiome Research Reports · doi:10.20517/mrr.2024.57 · Cited by 14
Sun, J., Fu, X., Liu, Y., Wang, T., Zhao, X., Cui, R., & Yang, W. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70630 · Cited by 9
“Studies have shown that the GLP- 1R-related pathway expressed in microglia can reduce inflammation, promote neurogenesis, provide neurotrophic effects and restore insulin signalling in neurons [12, 16–18].”
Zhang, X., Chi, R., Xu, J., Meng, C., Wang, Z., Ruo, W., Xin, F., Xu, T., Guo, F., Wang, G., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116010 · Cited by 7
GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review
Orozco, M. P., Rivadeneira, V. V., & León-Rojas, J. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412163 · Cited by 8
“GLP-1RAs have also been reported to inhibit Toll-like receptor (TLR)-induced inflammatory responses in the CNS [32], suggesting a broad dampening of innate immune activation.”
InfluentialThe critical role of GLP-1 signaling pathways in the pathology of Parkinson's disease and diabetes
Chen, J., Dong, X., Lin, Y., & Lv, C. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155985 · Cited by 7
Zhao, F., Wang, H., Li, S., Yun, H., & Su, W. (2026) · PeerJ · doi:10.7717/peerj.20710 · Cited by 6
Parkinson’s disease and brain insulin signaling: Mechanisms and potential role of GLP-1 mimetics
Foroozanmehr, B., Hemmati, M. A., Yaribeygi, H., Karav, S., Jamialahmadi, T., & Sahebkar, A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149738 · Cited by 6
Elezz, A. M. A., khalefa, K. A., Gadelmawla, A. F., Khattab, Y. A., & Zeid, M. A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01873-0 · Cited by 8
Cosmetic Considerations of Semaglutide
Baggett, A. D., Saadi, C. C., Saadi, R. A., & Patel, V. (2025) · Cosmetics · doi:10.3390/cosmetics12050221 · Cited by 6
Sources of Oxidative Stress in Parkinson’s Disease: Pathways and Therapeutic Implications
Yordanov, Y., Stefanova, D., Kondeva-Burdina, M., & Tzankova, V. (2026) · Antioxidants · doi:10.3390/antiox15020187 · Cited by 8
“Also reduce microglial activation and pro-inflammatory signaling in brain [157].”
The Link between Salivary Amylase Activity, Overweight, and Glucose Homeostasis
Erta, G., Gersone, G., Jurka, A., & Tretjakovs, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189956 · Cited by 7
Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Diseases: A Comprehensive Review
Ibrahim, R., Kambal, A., & Abdelmajeed, M. A. (2025) · Cureus · doi:10.7759/cureus.92441 · Cited by 11
“Finally, through stabilization of I-kappa-B-alpha (I κ B α ), there is downregulation of inflammasome-mediated cytokine release and the overall reduction of the pro-inflammatory cytokine environment in the CNS, further protecting the BBB [39].”
Joo, J. H., Zhao, A., Chalasani, M., Allan, K. C., & Rachitskaya, A. V. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.12.014 · Cited by 6
GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care
Șufaru, I.-G., Vasiliu, B. C., Hăncianu, M., Stratul, Ş., Tatarciuc, M., Iovan, G., Tatarciuc, D., Rudnic, I., Hanu, D., Paduraru, S., et al. (2026) · Biomolecules · doi:10.3390/biom16060857 · Cited by 7
“Current mechanistic reviews consistently describe anti-inflammatory effects, including reducing pro-inflammatory signaling cascades, lowering cytokine production, and modulating immune cell activity [47–52].”
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16434 · Cited by 7
“56,57 However, the increased delirium risk observed during mid-term follow-up raises concerns that prolonged exposure may not sustain these neuroprotective benefits and could introduce new vulnerabilities.”
Tang, H., Donahoo, W. T., DeKosky, S. T., Lee, Y. A., Kotecha, P., Svensson, M., Bian, J., & Guo, J. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70313 · Cited by 5
Richard, J. E., Mohammad, A., Go, K. A., McGovern, A. J., Rechlin, R. K., Splinter, T. F. L., Lieblich, S. E., Radovic, L. K., Feng, L., Blankers, S. A., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106088 · Cited by 4
Milori, P. H., Armelin, L. M., Mutarelli², A. M., & Caramelli, P. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251395086 · Cited by 5
“45 These agents appear to modulate neuroin fl ammation by promoting an anti-in fl ammatory microglial phenotype, 46 reduce oxidative stress and preserve mitochondrial and cellular integrity, 47 improve brain insulin signaling through the PI3 K/Akt pathway, 48 inhibit neuronal apoptosis by modulating…”
NLRP3 inflammasome as a central target for the pleiotropic effects of GLP-1 receptor agonists
Mahmoudi, A. A., Saeedi‐Boroujeni, A., Vadizadeh, A., Kesharwani, P., & Sahebkar, A. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117063 · Cited by 4
Goddard, G., Rajagopal, S., Makhoul, G. W., & Raji, M. A. (2025) · Life · doi:10.3390/life15091370 · Cited by 5
“GLP1RA, developed to treat T2DM, has been found to possess some anti-inflammatory and antioxidant properties, part of the pathogenesis of various diseases [58].”
Costa, G. V. L., Cavalcante, L. F. F., Battistuta, S. M., Makabe, P. F., Bueno, I. S. F., Yuamoto, B., Vilela, F., Meloni, L. G. G., de Faria, D. D., Anghinah, R., et al. (2025) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200548 · Cited by 3
Feghali, J., Ruchika, F., Horowitz, M. A., Xu, R., Jackson, C. M., Caplan, J. M., Huang, J., Tamargo, R. J., & Gonzalez, L. F. (2026) · Stroke · doi:10.1161/strokeaha.125.053599 · Cited by 3
Li, Q.-M., Zhang-Yang, Q.-Q., Tan, Y.-Y., Wu, X.-L., Zha, X., Shang, Z.-Z., Luo, J., & Zhang, F. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151235 · Cited by 3
GLP-1 Receptor Agonist Use and Survival Among Patients With Type 2 Diabetes and Brain Metastases
Chi, K., Chang, Y., Song, J., Chen, C., Perng, P.-S., & Lin, H.-M. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.1311 · Cited by 3
Morsy, M. M., Hassan, H. A., Morsi, R. M., Nafea, O. E., Farag, A. I., & Ramadan, R. S. (2024) · Reproductive Toxicology · doi:10.1016/j.reprotox.2024.108826 · Cited by 3
Blossom, V., Ullal, S. D., Rai, R., Hegde, A., Rai, S., & Anita Sherly, A. (2026) · Oxygen · doi:10.3390/oxygen6020006 · Cited by 3
“Moreover, pioglitazone ameliorated cognitive impairment induced by the chemotherapy drug doxorubicin in the rat model, and it was achieved by reducing neuroinflammation, oxidative stress, and lipid peroxidation [71].”
Knezović, A., Hosch, M., Hamann, C. S., Popp, S., Ortega, G., Barilar, J. O., Grünblatt, E., Monoranu, C., Riederer, P. F., Šalković‐Petrišić, M., et al. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02979-z · Cited by 5
Moțățăianu, A., Mănescu, I. B., Şerban, G. M., Ion, V., Bălașa, R., & Andone, S. R. (2025) · Nutrients · doi:10.3390/nu17091437 · Cited by 2
“Likewise, Diz-Chaves et al. endorse using GLP-1 receptor agonists as a promising therapeutic strategy, emphasizing their ability to evoke an anti-inflammatory response in neurodegenerative disorders [33].”
Zohora, F. T., Mou, S. S., Haque, M. R., Baidya, M., Jahan, I., & Al-Mamun, M. E. (2025) · Translational Medicine of Aging · doi:10.1016/j.tma.2025.08.005 · Cited by 2
Helal, M. M., Almosilhy, N. A., Abo‐elnour, D. E., Jaffal, R., Allam, E. G., Almosilhy, M. A., Batarseh, S. F., & Meshref, M. M. (2026) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2026.2627901 · Cited by 3
“…suggests that GLP-1RAs exert pleiotropic effects on key ALS-relevant mechanisms, including neuroinflammation, neuroprotection, and neurotrophic signaling, making them promising candidates for ALS and other NDGs, particularly given the limited efficacy of single-target therapies in ALS (163–168).”
Targeting TLR4 in Parkinson's disease: mechanisms and therapeutic prospects
Dong, S., Lu, J., Wu, L., Wang, S., 宫玉波, Hu, J., Liu, Y., & Chen, X. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116780 · Cited by 2
Dahshan, A., Khalil, M. I. M., El-Jaafary, S. I., & Yamani, A. (2026) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2026.100461 · Cited by 2
“GLP-1RAs suppress activation of the NLRP3 inflammasome, reduce interleukin-1 β (IL-1 β ) and tumor necrosis factor-α (TNF-α ) secretion, and promote microglial polarization from the pro-inflammatory M1 phenotype toward the anti-inflammatory M2 phenotype [7].”
Metabolic resilience: liraglutide’s potential in alleviating depressive symptoms
Gammoh, O., Qnais, E. Y., Aljabali, A. A. A., Hatahet, T., & Alqudah, A. M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10641-w · Cited by 2
Song, T., Wang, B., Li, Y., Zhao, Y., Li, J., Wang, Y., & Li, X. (2025) · Mediators of Inflammation · doi:10.1155/mi/8217035 · Cited by 182
Liao, B., Ding, L., Chen, W., Yue, M., Wang, Y., Hong, D., Chen, T., & Fang, X. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10638-8 · Cited by 6
Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects
Kim, K. S., Park, J. S., & Choi, H. J. (2025) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2448320.160 · Cited by 3
“…pathways regulate synaptic plasticity by regulating pathways related to N-Methyl-D-aspartic acid (NMDA) and aminomethylphosphonic acid receptor signaling such as calcium influx into intracellular membranes to change synaptic plasticity for long-term potentiation related to memory function [42-45].”
Thome, A. D., Thonhoff, J. R., Wang, J., Berman, H., Grossman, F., & Appel, S. H. (2025) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2025-0001 · Cited by 1
Metadata
- Authors
- Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F.
- Affiliations
- Universidade de Vigo (ES)
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212 Vigo, Spain
- Corresponding author
- Diz-Chaves, Yolanda
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-08-24
- Volume
- 23
- Issue
- 17
- Pages
- 9583
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9455625
- OpenAlex
- W4293001879
- Cited by
- 148
- References
- 211
- Citations by year
- 2026: 52 · 2025: 66 · 2024: 21 · 2023: 9
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Investigo Institutional repository of UVigo (Universidade de Vigo) (submittedVersion, cc-by)
- Funders
- European Union Grant Alehoop (H2020-BBIJTI-2019-887259, ED431G/02)
- Xunta de Galicia (Centro singular de Investigación de Galicia accreditation 2016–2019) (H2020-BBIJTI-2019-887259, ED431G/02)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- glucagon-like peptide-1, GLP-1 receptor, neuroinflammation, neurodegenerative diseases, neuroprotection, anti-inflammatory activity, brain, GLP-1 receptor signaling, therapeutic target
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Brain, Humans, Inflammation, Neurodegenerative Diseases, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.